Payment overview · 2025
General Payments
$155.44
9 reported records · 6 companies
Healthcare provider profile · identity verified
Michael J Ferguson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · OLATHE, KS · NPI 1700873932
Verified facts
What the public records show
CMS Open Payments records show Michael J Ferguson, D.O. received $155.44 in general payments during 2025 across 9 reported records.
Astellas Pharma US Inc accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.46 | 23.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.54 | 22.2% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $29.19 | 18.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.89 | 15.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.05 | 11.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.31 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $155.44 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $29.19 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 47 |
| Methylprednisolone | Methylprednisolone | 155 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 131 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 131 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 30 |
| Famotidine | Famotidine | 126 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 31 |
| Azithromycin | Azithromycin | 113 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 36 |
| Dexamethasone | Dexamethasone | 105 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 38 |
| Prednisone | Prednisone | 97 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 92 | 27 |
| Clonazepam | Clonazepam | 88 | 18 |
| Tramadol Hcl | Tramadol Hcl | 82 | 14 |
| Losartan Potassium | Losartan Potassium | 78 | 25 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 75 | 21 |
| Alprazolam | Alprazolam | 74 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 22 |
| Montelukast Sodium | Montelukast Sodium | 66 | 22 |
| Potassium Chloride | Potassium Chloride | 62 | 16 |
| Simvastatin | Simvastatin | 59 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | 11 |
| Meloxicam | Meloxicam | 55 | 14 |
| Anastrozole | Anastrozole | 53 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 53 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 14 |
| Cephalexin | Cephalexin | 47 | 40 |
| Omeprazole | Omeprazole | 46 | 13 |
| Ozempic | Semaglutide | 46 | suppressed |
| Metformin Hcl | Metformin Hcl | 45 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 30 |
| Ibandronate Sodium | Ibandronate Sodium | 43 | 11 |
| Diazepam | Diazepam | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 30 |
| Gabapentin | Gabapentin | 39 | 11 |
| Carvedilol | Carvedilol | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 15 |
| Lactulose | Lactulose | 35 | 17 |
| Metformin Hcl Er | Metformin Hcl | 35 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 12 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Furosemide | Furosemide | 32 | 11 |
| Guanfacine Hcl Er | Guanfacine Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Armour Thyroid | Thyroid,pork | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 28 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 16 |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Lisinopril | Lisinopril | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 14 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $155.44 · 9 records | Astellas Pharma US Inc | AIRSUPRA, JOURNAVX, QULIPTA, UBRELVY, Veozah, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error